Tizona Therapeutics

About:

Tizona develops next-generation immunotherapies

Website: http://tizonatx.com/

Top Investors: Canaan Partners, Astellas Venture Management, Gilead Sciences, Amgen Ventures, Abingworth

Description:

The company is establishing collaborations with its scientific founders “to better understand whether regulatory T cells play a more prominent role in certain tumors,” he added. Although research suggests that Tregs cells play a more prominent role in creating immunosuppression in the microenvironment in some tumor types than others, “quite honestly, the data are lacking. One of the ways we’re going to differentiate the company is to understand that relationship better.

Total Funding Amount:

$370M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

South San Francisco, California, United States

Founded Date:

2014-01-01

Contact Email:

info(AT)tizonatx.com

Hub Tags:

Emerging Unicorn

Founders:

Charles Drake, Dario Vignali, Drew Pardoll, Jedd Wolchok, Vijay Kuchroo

Number of Employees:

11-50

Last Funding Date:

2020-07-21

IPO Status:

Private

© 2025 bioDAO.ai